Free Trial

The Global Times notes that.............>

MARKET TALK
MARKET TALK: The Global Times notes that "innovative Chinese biopharmaceutical
firm CanSino Biologics Inc announced on Monday that a recombinant novel
coronavirus vaccine (Ad5-nCoV) the company developed with a military research
team has received special military drug approval, with a validity of one year.
Ad5-nCoV is currently limited to military use and cannot be expanded to a
broader vaccination range without the approval of the Health Bureau of the
Logistics Support Department under the Central Military Commission, the company
said in a statement filed with Hong Kong Exchanges and Clearing Ltd. The vaccine
is being jointly developed by CanSino and the Institute of Biotechnology under
the Academy of Military Medical Sciences. The company said on March 18 that
Ad5-nCoV had won approval for clinical trials."
MNI London Bureau | +44 0203-865-3809 | anthony.barton@marketnews.com
MNI London Bureau | +44 0203-865-3809 | anthony.barton@marketnews.com

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.